Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Open Access
- 18 April 2023
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0005323
Abstract
HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB arm and 42 in the TDF-FTC arm).Keywords
Funding Information
- HHS | National Institutes of Health (UM1AI068619)
- HHS | National Institutes of Health (UM1AI068617)
- HHS | National Institutes of Health (UM1AI068613)
- ViiV Healthcare
- Gilead Sciences
This publication has 16 references indexed in Scilit:
- Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083The Journal of Infectious Diseases, 2021
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialThe Lancet HIV, 2020
- Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialPLOS Medicine, 2018
- Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed TherapyAntimicrobial Agents and Chemotherapy, 2018
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialThe Lancet HIV, 2017
- Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)AIDS Research and Human Retroviruses, 2016
- Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency VirusScience, 2014
- Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer InhibitorHIV Research & Clinical Practice, 2013
- Flip-flop Pharmacokinetics – Delivering a Reversal of Disposition: Challenges and Opportunities During Drug DevelopmentTherapeutic Delivery, 2011
- Web Resources for HIV Type 1 Genotypic-Resistance Test InterpretationClinical Infectious Diseases, 2006